Tecentriq for Locally Advanced or Metastatic Urothelial Carcinoma
Tecentriq (atezolizumab, Genetech)
Indications: Patients with locally advanced or metastatic urothelial carcinoma
- Not eligble for cisplatin-containing chemotherapy & whose tumors express PD-L1
- Not eligible for any platinum-containing chemotherapy regardless of PD-L1 status
- Have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy
Dosage
- Metastatic Urothelial Carcinoma or Previously Treated NSCLC
- 1200 mg intravenously 60 mins x 3weeks
- 1200 mg IV over 60 minutes, followed by bevacizumab, paclitaxel and carboplatin, on the same day every 3 weeks x4-6
Contraindications: none
Recent Videos
Related Content
